Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guglielmo Borgia

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
Expert Review of Anti-Infective Therapy|July 31, 2014
Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infectionIvan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia
Infectious Diseases (London, England)|March 21, 2017
Hepatitis B mother-to-child transmission and infants immunization: we have not come to the end of the story yetGuglielmo Borgia, Alberto Enrico Maraolo, Ivan Gentile
Expert Opinion on Investigational Drugs|April 5, 2019
An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacyGuglielmo Borgia, Riccardo Scotto, Antonio Riccardo Buonomo
Expert Review of Anti-Infective Therapy|September 7, 2016
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?Ivan Gentile, Alberto Enrico Maraolo, Guglielmo Borgia
Reviews on Recent Clinical Trials|June 3, 2014
Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus InfectionIvan Gentile, Antonio R Buonomo, Guglielmo Borgia
Gastroenterology|September 7, 2005
CpG and Toll-like receptor 9 in primary biliary cirrhosis: a possible intracellular interaction from virus exposure?Alessandro Perrella, Guglielmo Borgia, Marco Perrella, et al.
Therapeutics and Clinical Risk Management|May 14, 2009
Tenofovir and its potential in the treatment of hepatitis B virusLaura Reynaud, Maria Aurora Carleo, Maria Talamo, et al.
Le Infezioni in Medicina|March 22, 2014
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Expert Review of Anti-Infective Therapy|June 12, 2014
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Expert Opinion on Investigational Drugs|November 12, 2014
Discontinued drugs in 2012 - 2013: hepatitis C virus infectionIvan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
Expert Review of Anti-Infective Therapy|July 31, 2014
Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infectionIvan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia
Infectious Diseases (London, England)|March 21, 2017
Hepatitis B mother-to-child transmission and infants immunization: we have not come to the end of the story yetGuglielmo Borgia, Alberto Enrico Maraolo, Ivan Gentile
Expert Opinion on Investigational Drugs|April 5, 2019
An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacyGuglielmo Borgia, Riccardo Scotto, Antonio Riccardo Buonomo
Expert Review of Anti-Infective Therapy|September 7, 2016
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?Ivan Gentile, Alberto Enrico Maraolo, Guglielmo Borgia
Reviews on Recent Clinical Trials|June 3, 2014
Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus InfectionIvan Gentile, Antonio R Buonomo, Guglielmo Borgia
Gastroenterology|September 7, 2005
CpG and Toll-like receptor 9 in primary biliary cirrhosis: a possible intracellular interaction from virus exposure?Alessandro Perrella, Guglielmo Borgia, Marco Perrella, et al.
Therapeutics and Clinical Risk Management|May 14, 2009
Tenofovir and its potential in the treatment of hepatitis B virusLaura Reynaud, Maria Aurora Carleo, Maria Talamo, et al.
Le Infezioni in Medicina|March 22, 2014
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Expert Review of Anti-Infective Therapy|June 12, 2014
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Expert Opinion on Investigational Drugs|November 12, 2014
Discontinued drugs in 2012 - 2013: hepatitis C virus infectionIvan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, et al.
Pageof 11